Roche CEO: Very Confident Will Reach Our Outlook

The transcript discusses the recovery and growth of a business, particularly in diagnostics and new medicines, despite the expected decline in COVID-19 testing growth. It covers the development of a COVID antiviral pill and the impact of COVID-19 on the cancer market. The timeline for an Alzheimer's drug is also discussed, along with the effects of inflation on business strategy and pipeline development.

What are the expectations for the Alzheimer's drug timeline?

How is inflation impacting the company's business operations?

What recent progress has the company made in its product pipeline?